Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…c MGMT-deficient G1/G2 PanNET treated with TMZ, with or without capecitabine, reportedly experienced histological progression to G3 disease …
…unother Cancer. 2019;7:214.Wong MK, Milhem MM, Sacco JJ, et al. RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (…
…8.9% were male and 51.1% were female. The most common ICIs were Pembrolizumab (16276, 45.38%), Nivolumab (10548, 29.41%), Ipilimumab (3120, 8…
…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…
…mmer R, Butler MO, Hill AG, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Me…
…treicher H, Sondak VK, Kirkwood JM. Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resecte…
…comes, and overall survival (OS) in NSCLC patients treated with nivolumab.Methods This observational, multicenter, prospective study enro…
… the incidence and severity of irAEs in melanoma patients using nivolumab, along with the management and outcomes of irAEs, and the overa…
…an age was 63.8 years. The most common first-line regimens were nivolumab (N) + cabozantinib (44.1%), N + ipilimumab (26.5%), pembrolizum…
…23–34.Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cel…
…vo, supporting its evaluation in combination with nivolumab and ipilimumab.Methods This is an investigator-initiated, phase 1, dose-escala…
…t-remission, one of whom achieved CR after salvage therapy with nivolumab. Among the 4 patients who were treated with relatlimab and nivo…